Risk Stratification Directed Conditioning Regimen for Haploidentical HSCT in SAA
Status:
Recruiting
Trial end date:
2022-03-30
Target enrollment:
Participant gender:
Summary
The haplotype HSCT system including Bu(0.8mg/kg Q6hx2d)CTX(50mg/kgx4d)rATG(2.5mg/kgx4d) ,
established in Institute of Hematology of Peking University ,has been evaluated to be
effective for acquired SAA.But some patients with high risk factors may not tolerate CTX
200mg/kg,alternative conditioning regimen including Bu/Fludarabine/dercreased CTX was studied
in this trial.